Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.

Autor: Loyal L; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Braun J; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Henze L; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Kruse B; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Dingeldey M; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Reimer U; JPT Peptide Technologies GmbH, Berlin, Germany., Kern F; JPT Peptide Technologies GmbH, Berlin, Germany.; Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK., Schwarz T; Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Mangold M; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Unger C; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Dörfler F; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany., Kadler S; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany., Rosowski J; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany., Gürcan K; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany., Uyar-Aydin Z; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany., Frentsch M; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Therapy-Induced Remodeling in Immuno-Oncology, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany., Kurth F; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schnatbaum K; JPT Peptide Technologies GmbH, Berlin, Germany., Eckey M; JPT Peptide Technologies GmbH, Berlin, Germany., Hippenstiel S; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany., Hocke A; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany., Müller MA; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany., Sawitzki B; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Miltenyi S; Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany., Paul F; Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Clinical Neuroimmunology, NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany., Mall MA; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.; German Center for Lung Research, Associated Partner, Berlin, Germany., Wenschuh H; JPT Peptide Technologies GmbH, Berlin, Germany., Voigt S; Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany.; Institute for Virology, Universitätsklinikum Essen, Essen, Germany., Drosten C; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany., Lauster R; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany., Lachman N; Institute for Transfusion Medicine, Tissue Typing Laboratory, Charité - Universitätsmedizin Berlin, Berlin, Germany., Sander LE; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany., Corman VM; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany., Röhmel J; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany., Meyer-Arndt L; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Clinical Neuroimmunology, NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Thiel A; Si-M/'Der Simulierte Mensch,' a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Giesecke-Thiel C; Max Planck Institute for Molecular Genetics, Berlin, Germany.
Jazyk: angličtina
Zdroj: Science (New York, N.Y.) [Science] 2021 Oct 08; Vol. 374 (6564), pp. eabh1823. Date of Electronic Publication: 2021 Oct 08.
DOI: 10.1126/science.abh1823
Abstrakt: The functional relevance of preexisting cross-immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a subject of intense debate. Here, we show that human endemic coronavirus (HCoV)–reactive and SARS-CoV-2–cross-reactive CD4 + T cells are ubiquitous but decrease with age. We identified a universal immunodominant coronavirus-specific spike peptide (S816-830) and demonstrate that preexisting spike- and S816-830–reactive T cells were recruited into immune responses to SARS-CoV-2 infection and their frequency correlated with anti–SARS-CoV-2-S1-IgG antibodies. Spike–cross-reactive T cells were also activated after primary BNT162b2 COVID-19 messenger RNA vaccination and displayed kinetics similar to those of secondary immune responses. Our results highlight the functional contribution of preexisting spike–cross-reactive T cells in SARS-CoV-2 infection and vaccination. Cross-reactive immunity may account for the unexpectedly rapid induction of immunity after primary SARS-CoV-2 immunization and the high rate of asymptomatic or mild COVID-19 disease courses.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje